drugset / Trial / NCT01382940
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
NaSingle-groupOpen-labelTreatment
Summary
This study was designed to evaluate the safety of administering rituximab at a more rapid infusion rate in patients with moderate to severe rheumatoid arthritis who have had an inadequate response to biopharmaceuticals that treat diseases by interfering with tumor necrosis factor (anti-TNF therapies), and were receiving methotrexate therapy for more than eight weeks.
Timeline
- Start
- 2011-07-26
- Primary completion
- 2013-01-06
- Completion
- 2013-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |
| Background | Acetaminophen | Small molecule | 1 g | Oral |
| Background | Diphenhydramine | Unknown | 50 mg | Oral |
| Background | Methotrexate | Small molecule | 10 mg | Oral |
| Background | Methotrexate | Small molecule | 25 mg | Oral |
| Background | Methylprednisolone | Other / unclassified | 100 mg | Intravenous |